New York, USA – April 28, 2021 – Cancer is one of the leading causes of human death. Traditional treatment options, including surgery, radiotherapy and chemotherapy, are hardly applicable to all patients. However, with recent success, immunotherapy has emerged as a pragmatic strategy and a reputable pillar of cancer treatment, improving the prognosis of many patients suffering from different malignancies, thus completely revolutionizing cancer treatment methods.
Chimeric antigen receptor (CAR) engineering can redirect the specificity of immune effector cells, converting them to a much more potent weapon to combat cancer cells. As a well-known participant in the field of immunotherapy research, Creative Biolabs has established a strong network of academic and industrial collaborators to promote the development of CAR cell therapy.
CAR-T cell therapy and TCR-T cell therapy involve binding proteins called chimeric antigen receptors to activated T cells extracted from the patient. These receptors are artificially designed to target the naturally occurring antigens on the surface of cancer cells. This enables patients to receive treatment for cancers that the body would not combat on its own. The difference between the two methods pertains to what antigens they are capable of recognizing.
In addition, other CAR cell-based therapies, including CAR-NK cell therapy, CAR-Macrophage (CAR-MA) therapy, and CAR-B cell therapy, are all available at Creative Biolabs. These cell-based therapies are complex and innovative new therapeutic approaches that play a key role in eliminating solid tumors.
CAR-NK cell therapy is a novel type of immunotherapy designed to enhance the cancer-fighting power of NK cells. A molecule called a chimeric antigen receptor (CAR) is added to the NK cells. With this addition, the new CAR NK cells can now identify and attack a target on the surface of the previously “invisible” cancer cell. Current research has focused on a specific target molecule called CD19, which is found on certain cancer cells.
CAR-T cell therapy is often hampered by the inability of T cells to penetrate solid tumors, as well as the inhibitory tumor microenvironment (TME). However, research scientists transduced CARs into macrophages (CAR-MA) to show that CAR-MA therapy could efficiently contribute to the antitumor response.
CAR-B cell therapy has also shown a significant ability to eliminate a wide range of tumors. Using the CRISPR/Cas9 system, algorithms will be designed to develop effective knockout strategies to remove endogenous BCR (B cell receptor) expression from B cell lines.
The making of CAR cell therapies is a highly complicated endeavor requiring both a gene-therapy manufacturing process (often including viral vectors) and the process of collecting cells, genetically modifying and expanding them, and preparing them for patients. These multistep technologies and logistics are rife with risk. To address some of these challenges, Creative Biolabs is confident in ensuring every step in the process of developing CAR cell therapies to be rigorously scrutinized from research to clinical trial.
About Creative Biolabs
Creative Biolabs, an experienced biotech company, is the leader in CAR cell therapy development with best-class technology and highly specialized solutions that focused on enabling and accelerating the rapid development and commercialization of cell-based products and services for customers.